PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS

1 . A compound having the structure of Formula I, Formula II, or Formula III, or a pharmaceutically acceptable salt or N-oxide thereof:

wherein:

ring T is an aryl or heteroaryl ring;

R 1 is H, or substituted or unsubstituted alkyl;

R 2 is unsubstituted alkyl or alkyl substituted with substituted or unsubstituted amino, amido, nitro, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, aryloxy, alkoloxo, amide, ester, alkoyl, cyano, aryl, or heteroaryl; substituted or unsubstituted alkoxy; substituted or unsubstituted aralkoxy; substituted or unsubstituted heteroalkyl; substituted or unsubstituted cycloalkyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted heterocycloalkyl; substituted or unsubstituted heterocycloalkylalkyl; spiro -cycloakyl-heterocycloalkyl; -alkylene-S(═O)R 9 ; -alkylene-S(═O) 2 R 9 ; or —S(═O) 2 R 9 ;

R 3 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroarylalkyl;

R 4 is substituted or unsubstituted heteroaryl attached to ring T or the phenyl ring via a carbon atom of R 4 , or substituted or unsubstituted heterocycloalkyl attached to ring T or the phenyl ring via a carbon atom of R 4 ;

each R 5 is independently halogen, —CN, —NO 2 , —OH, —OCH 2 F, —OCF 2 H, —CF 3 , —SR 8 , —NR 10 S(═O) 2 R 9 , —S(═O) 2 N(R 10 ) 2 , —S(═O)R 9 , —S(═O) 2 R 9 , —C(═O)R 9 , —OC(═O)R 9 , —CO 2 R 10 , —N(R 10 ) 2 , —C(═O)N(R 10 ) 2 , —NR 10 C(═O)R 10 , —NR 10 C(═O)OR 10 , —NR 10 C(═O)N(R 10 ) 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heterocycloalkyl; or substituted or unsubstituted cycloalkyl; or substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;

each R 8 is independently H or R 9 ;

each R 9 is independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each R 10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or two R 10 , together with the atoms to which they are attached form a heterocycle; and

s is 0-4.

2 . The compound of claim 1 having the structure of Formula Ib:

wherein s is 0-3.

3 . The compound of claim 1 having the structure of Formula IIIa:

wherein s is 0-3.

4 . The compound of claim 1 , wherein R 4 is a substituted or unsubstituted C-linked heteroaryl.

5 . The compound of claim 4 wherein R 4 is selected from pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, benzofuranyl, benzimidazolyl, indazolyl, pyrrolopyridinyl, and imidazopyridinyl.

6 . The compound of claim 1 , wherein each R 5 is independently halogen, —N(R 10 ) 2 , or a substituted or unsubstituted alkyl.

7 . The compound claim 1 , wherein R 3 is a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted heterocycloalkyl.

8 . The compound of claim 7 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

9 . The compound of claim 7 , wherein heterocycloalkyl is pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, or piperazinyl.

10 . The compound of claim 1 , wherein R 3 is a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted arylalkyl, or a substituted or unsubstituted heteroarylalkyl.

11 . The compound of claim 1 , wherein R 2 is unsubstituted alkyl or alkyl substituted with substituted or unsubstituted amino, amido, nitro, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, amide, ester, alkoyl, cyano, aryl, or heteroaryl.

12 . The compound of claim 1 , wherein R 2 is a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted cycloalkylalkyl, or a substituted or unsubstituted heterocycloalkylalkyl.

13 . The compound of claim 12 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

14 . The compound of claim 12 , wherein heterocycloalkyl is pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, or piperazinyl.

15 . The compound of claim 1 , wherein R 1 is H.

16 . A compound selected from:

or a pharmaceutically acceptable salt or N-oxide thereof.

17 . A method for treating a cancer in an individual in need thereof, comprising administering to the subject a therapeutically effective amount of a compound having the structure of Formula I, Formula II, or Formula III, or a pharmaceutically acceptable salt or N-oxide thereof:

wherein:

ring T is an aryl or heteroaryl ring;

R 1 is H, or substituted or unsubstituted alkyl;

R 2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aralkoxy, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkylalkyl, spiro -cycloakyl-heterocycloalkyl, -alkylene-S(═O)R 9 , -alkylene-S(═O) 2 R 9 , —S(═O) 2 R 9 ;

R 3 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroarylalkyl;

R 4 is substituted or unsubstituted heteroaryl attached to ring T or the phenyl ring via a carbon atom of R 4 , or substituted or unsubstituted heterocycloalkyl attached to ring T or the phenyl ring via a carbon atom of R 4 ;

each R 5 is independently halogen, —CN, —NO 2 , —OH, —OCF 3 , —OCH 2 F, —OCF 2 H, —CF 3 , —SR 8 , —NR 10 S(═O) 2 R 9 , —S(═O) 2 N(R 10 ) 2 , —S(═O)R 9 , —S(═O) 2 R 9 , —C(═O)R 9 , —OC(═O)R 9 , —CO 2 R 10 , —N(R 10 ) 2 , —C(═O)N(R 10 ) 2 , —NR 10 C(═O)R 10 , —NR 10 C(═O)OR 10 , —NR 10 C(═O)N(R 10 ) 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heterocycloalkyl; or substituted or unsubstituted cycloalkyl; or substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;

each R 8 is independently H or R 9 ;

each R 9 is independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each R 10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or two R 10 , together with the atoms to which they are attached form a heterocycle; and s is 0-4.

18 . The method of claim 17 , wherein the cancer is a breast cancer, colorectal cancer, brain cancer, lung cancer, pancreatic cancer, kidney cancer, skin cancer, cancer of the central nervous system, liver cancer, stomach cancer, gastrointestinal cancer, ovarian cancer, leukemia, or lymphoma.

19 . The method of claim 18 , wherein the brain cancer is a glioblastoma.

20 . The method of claim 18 , wherein the cancer of the central nervous system is a tumor associated with neurofibromatosis type 1 or neurofibromatosis type 2.